https://www.selleckchem.com/pr....oducts/b102-parp-hda
Myeloablative conditioning regimens decrease the risk of relapse in pediatric patients undergoing allogeneic hematopoietic stem cell transplant (HCT) for hematologic malignancies, but cause significant toxicities PROCEDURE This prospective study evaluated the use of a reduced-toxicity, myeloablative regimen with dose-adjusted busulfan, fludarabine, antithymocyte globulin and 400 cGy of total body irradiation in 40 patients21 years of age undergoing HCT for high-risk leukemias. Busulfan pharmacokinetics were measured to t
Like
Comment
Share
